The Biomarker Summit 2013 will discuss a wide range of issues such as biomarker identification and validation strategies, patient stratification, enabling omics technologies, regulatory and reimbursement trends, and the development of companion diagnostics.
These areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector.
The event will be held from March 20 to 22 in San Francisco.
The event starts with a plenary keynote session with the following speakers:
Charles Cantor, chief scientific officer, Sequenom
Daniel Chan, professor and director, Clinical Chemistry Division, Johns Hopkins University
Nicholas Dracopoli, vice president, head of Oncology Biomarkers, Janssen Research & Development
Kenneth Rhodes, vice president, neurology research, Biogen Idec
Sudhir Srivastava, chief, Cancer Biomarkers Research Group, National Cancer Institute, NIH
Scientists, researchers, decision-makers, and others will convene to discuss the latest biomarker developments in three major therapeutic areas, formally organized in the following tracks:
Click here to download a brochure.
[Source: Biomarker Summit 2013]
